Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene, combined with the prodrug ganciclovir (GCV) medication, is a promising approach for the treatment of malignant tumors, including prostate cancer. The success of this therapeutic strategy requires tissue- or tumor-specific gene expression and efficient gene delivery. In this chapter, we describe the experimental protocols of key methodologies, including promoter construction, reporter assay, adenoviral vector construction and preparation, HSV-tk enzymatic assay and cytotoxicity assay to evaluate the specificity and efficacy of osteonectin promoter-mediated HSV-tk/GCV suicide gene therapy of prostate cancer.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Number of pages16
Publication statusPublished - Jan 1 2019

Publication series

NameMethods in Molecular Biology
ISSN (Print)1064-3745


  • Adenoviral vector
  • HSV-tk enzymatic assay
  • Osteonectin promoter construction
  • Prostate cancer
  • Suicide gene therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics


Dive into the research topics of 'Osteonectin promoter-mediated suicide gene therapy of prostate cancer'. Together they form a unique fingerprint.

Cite this